GITR (TNFRSF18)
GITR is an accelerator on T cells that agonist antibodies tried to press to boost immunotherapy. Several reached early trials; one programme was dropped for reasons unrelated to safety.
Overview
TNFRSF18 (chromosome 1p36.33) encodes GITR, the receptor for TNFSF18 (GITR ligand), which seems to be involved in interactions between activated T lymphocytes and endothelial cells and in the regulation of T-cell-receptor-mediated cell death, and mediates NF-kappa-B activation through the TRAF2/NIK pathway; it is expressed in lymph node and peripheral blood leukocytes and weakly in spleen (UniProt Q9Y5U5). BMS-986156, a GITR agonist, completed phase 1/2 alone and with nivolumab (NCT02598960); TRX518 was discontinued for reasons unrelated to safety (NCT03861403).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GITR is an accelerator on T cells that agonist antibodies tried to press to boost immunotherapy. Several reached early trials; one programme was dropped for reasons unrelated to safety.
- 1 · What it is
GITR is an accelerator on T cells that agonist antibodies tried to press to boost immunotherapy. Several reached early trials; one programme was dropped for reasons unrelated to safety.
- 2 · What goes wrong in cancer
A TNF-receptor-superfamily costimulator on activated and regulatory T cells.
- 3 · How drugs use it
No product in this corpus aims at GITR (TNFRSF18) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
External identifiers
Sources: HGNC HGNC:11914 (approved symbol, name, aliases and cross-references); UniProt Q9Y5U5 (protein name, function and tissue specificity)
Biology
A TNF-receptor-superfamily costimulator on activated and regulatory T cells.
- Lymph node and peripheral blood leukocytes (UniProt Q9Y5U5)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"GITR" OR ABSTRACT:"GITR" OR TITLE:"TNFRSF18" OR ABSTRACT:"TNFRSF18" OR TITLE:"AITR" OR ABSTRACT:"AITR" OR TITLE:"CD357" OR ABSTRACT:"CD357" OR TITLE:"TNF receptor superfamily member 18" OR ABSTRACT:"TNF receptor superfamily member 18") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GITR (TNFRSF18), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD27
Shares CD137 (4-1BB, TNFRSF9), The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab and the tag checkpoint-map.
- TargetKIR2DL1 (inhibitory KIR)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab and the tag checkpoint-map.
- TargetPVRIG (CD112R)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetLILRB1 (ILT2)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHHLA2 (B7-H7)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.